An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer

被引:190
作者
Greimel, E
Bottomley, A
Cull, A
Waldenstrom, AC
Arraras, J
Chauvenet, L
Holzner, B
Kuljanic, K
Lebrec, J
D'haese, S
机构
[1] Graz Univ, Dept Obstet & Gynecol, A-8036 Graz, Austria
[2] Eortc Data Ctr, Eortc Qual Life Unit, Brussels, Belgium
[3] Western Gen Hosp, Imperial Canc Res Fund, Psychol Res Grp, Edinburgh, Midlothian, Scotland
[4] Sahlgrens Univ Hosp, Gothenburg, Sweden
[5] Hosp Navarre, Pamplona, Spain
[6] Hop Hotel Dieu, Paris, France
[7] Univ Innsbruck, Dept Biol Psychiatry, A-6020 Innsbruck, Austria
[8] Univ Rijeka, Dept Obstet & Gynecol, Rijeka, Croatia
关键词
quality of life assessment; ovarian cancer; EORTC; questionnaire;
D O I
10.1016/S0959-8049(03)00307-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study defines the psychometric properties of the European Organisation for Research and Treatment of Cancer (EORTC) quality of life (QOL) questionnaire designed to measure the QOL of patients with ovarian cancer. The ovarian cancer module (EORTC QLQ-OV28) was developed to supplement the EORTC QLQ-C30. The core questionnaire and the QLQ-OV28 were prospectively administered to 368 ovarian cancer patients after they had been treated with radical or debulking surgery followed by chemotherapy. The QLQ-OV28 module assesses abdominal/gastrointestinal symptoms, peripheral neuropathy, other chemotherapy side-effects, hormonal/menopausal symptoms, body image, attitude to disease/treatment and sexual functioning. Questionnaires were well accepted by patients, baseline compliance rates were 86%, 72% provided a second assessment, less than 3% of the items had missing data. Multi-trait scaling analyses confirmed the hypothesised scales. All hypothesised scales exhibited good psychometric properties. These results support the clinical and psychometric validity of the EORTC QLQ-OV28 module as a supplement to the EORTC QLQ-C30. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1402 / 1408
页数:7
相关论文
共 16 条
  • [1] THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY
    AARONSON, NK
    AHMEDZAI, S
    BERGMAN, B
    BULLINGER, M
    CULL, A
    DUEZ, NJ
    FILIBERTI, A
    FLECHTNER, H
    FLEISHMAN, SB
    DEHAES, JCJM
    KAASA, S
    KLEE, M
    OSOBA, D
    RAZAVI, D
    ROFE, PB
    SCHRAUB, S
    SNEEUW, K
    SULLIVAN, M
    TAKEDA, F
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) : 365 - 376
  • [2] Chemotherapy for ovarian cancer - a consensus statement on standard practice
    Adams, M
    Calvert, AH
    Carmichael, J
    Clark, PI
    Coleman, RE
    Earl, HM
    Gallagher, CJ
    Ganesan, TS
    Gore, ME
    Graham, JD
    Harper, PG
    Jayson, GC
    Kaye, SB
    Ledermann, JA
    Osborne, RJ
    Perren, TJ
    Poole, CJ
    Radford, JA
    Rustin, GJS
    Slevin, ML
    Smyth, JF
    Thomas, H
    Wilkinson, PM
    [J]. BRITISH JOURNAL OF CANCER, 1998, 78 (11) : 1404 - 1406
  • [3] Advanced epithelial ovarian cancer:: 1998 consensus statements
    Berek, JS
    Bertelsen, K
    du Bois, A
    Brady, MF
    Carmichael, J
    Eisenhauer, EA
    Gore, M
    Grenman, S
    Hamilton, TC
    Hansen, SW
    Harper, PG
    Horvath, G
    Kaye, SB
    Lück, HJ
    Lund, B
    McGuire, WP
    Neijt, JP
    Ozols, RF
    Parmar, MKB
    Piccart-Gebhart, MJ
    van Rijswijk, R
    Rosenberg, P
    Rustin, GJS
    Sessa, C
    Thigpen, JT
    Tropé, C
    Tuxen, MK
    Vergote, I
    Vermorken, JB
    Willemse, PHB
    [J]. ANNALS OF ONCOLOGY, 1999, 10 : 87 - 92
  • [4] The treatment of recurrent ovarian carcinoma: balancing patient desires, therapeutic benefit, cost containment and quality of life
    Bomalaski, JJ
    [J]. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 1999, 11 (01) : 11 - 15
  • [5] *CANC RES CAMP, 1997, FACTSH 17 1 OV CANC
  • [6] Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report
    Cull, A
    Howat, S
    Greimel, E
    Waldenstrom, AC
    Arraras, J
    Kudelka, A
    Chauvenet, L
    Gould, A
    [J]. EUROPEAN JOURNAL OF CANCER, 2001, 37 (01) : 47 - +
  • [7] CULL A, 2002, QUALITY LIFE STUDY P
  • [8] Fayers P., 2001, The EORTC QLQ-C30 scoring manual
  • [9] *JOINT COUNC CLIN, 1998, CURR ROL PACL 1 LIN
  • [10] Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
    McGuire, WP
    Hoskins, WJ
    Brady, MF
    Kucera, PR
    Partridge, EE
    Look, KY
    ClarkePearson, DL
    Davidson, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (01) : 1 - 6